01—Abstract
Summary
Summary of the 8-K filed October 3, 2025. Cited figures are marked; the original filing is the authoritative source.
On September 30, 2025, Halozyme Therapeutics, Inc. entered into an Agreement and Plan of Merger with Elektrofi, Inc., Erraid Merger Sub Inc. (a wholly-owned Halozyme subsidiary), and Shareholder Representative Services LLC, solely in its capacity as Securityholders' Representative.
Under the agreement, Merger Sub will merge into Elektrofi, which will survive as a wholly-owned subsidiary of Halozyme. Halozyme will pay aggregate upfront consideration of $750 milliona in cash, subject to customary adjustments for Elektrofi's debt, cash, transaction expenses and net working capital, plus up to three $50 million milestone payments contingent on three separate product regulatory approvals. A portion of Elektrofi employee stock options will be assumed by Halozyme and converted into options to acquire Halozyme common stock, which will reduce the cash portion of the Merger Consideration.
The merger is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes customary termination rights, including if the merger is not consummated within twelve months of the agreement date, subject to a six-month extension in certain circumstances. If the agreement is terminated under certain circumstances, Halozyme must pay Elektrofi a $36 millionb reverse termination fee in cash.
The filing attaches the Merger Agreement as Exhibit 2.1, with schedules omitted under Item 601(a)(5) of Regulation S-K and certain portions omitted under Item 601(b)(2), which Halozyme agrees to furnish to the SEC upon request. The filing also contains customary forward-looking statements, including risks that the transaction may not be consummated on the proposed terms or timing, or that required regulatory approvals may not be obtained or may be delayed.
02—Key points
Key Highlights
- Halozyme agreed to acquire Elektrofi, Inc. via a merger in which Elektrofi becomes a wholly-owned subsidiary of Halozyme.
- Upfront consideration is $750 million in cash, subject to customary adjustments for Elektrofi's debt, cash, transaction expenses and net working capital.
- Up to three $50 million milestone payments are payable, contingent on three separate product regulatory approvals.
- A portion of Elektrofi employee stock options will be converted into Halozyme common stock options, reducing the cash portion of the consideration.
- Closing is subject to customary conditions, including expiration or termination of the Hart-Scott-Rodino waiting period.
- Either party may terminate if the merger is not consummated within 12 months of the agreement date, subject to a six-month extension in certain circumstances.
- Halozyme must pay Elektrofi a $36 million cash reverse termination fee if the agreement is terminated under certain circumstances.
03—Questions
Frequently Asked Questions
How much will Halozyme pay to acquire Elektrofi?
Halozyme will pay aggregate upfront cash consideration of $750 million, subject to customary adjustments for Elektrofi's debt, cash, transaction expenses and net working capital, plus up to three $50 million milestone payments tied to separate product regulatory approvals.
What conditions must be met for the merger to close?
The merger is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
What happens if the merger is terminated?
Either party may terminate if the merger has not closed within twelve months of the agreement date, subject to a six-month extension in certain circumstances. Under certain termination scenarios, Halozyme must pay Elektrofi a $36 million cash reverse termination fee.
How will Elektrofi's employee stock options be treated?
A certain portion of Elektrofi stock options held by employees will be assumed by Halozyme and converted into options to acquire Halozyme common stock, which reduces the cash portion of the Merger Consideration payable.
Where can investors find the full terms of the deal?
The Merger Agreement is filed as Exhibit 2.1 to the current report. Schedules are omitted under Item 601(a)(5) of Regulation S-K, and certain portions are omitted under Item 601(b)(2); Halozyme agrees to furnish omitted materials to the SEC upon request.
04—Continue